109 related articles for article (PubMed ID: 28987791)
1. Serum interleukin measurement may help identify thyroid cancer patients with active disease.
Martins MB; Marcello MA; Batista FA; Peres KC; Meneghetti M; Ward MAL; Etchebehere ECSC; da Assumpção LVM; Ward LS
Clin Biochem; 2018 Feb; 52():1-7. PubMed ID: 28987791
[TBL] [Abstract][Full Text] [Related]
2. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
3. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
Zöphel K; Wunderlich G; Smith BR
Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
[TBL] [Abstract][Full Text] [Related]
4. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.
Elisei R; Vivaldi A; Agate L; Molinaro E; Nencetti C; Grasso L; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):33-9. PubMed ID: 14715824
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
6. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
[TBL] [Abstract][Full Text] [Related]
7. What is the role of florine-18 fluorodeoxyglucose/positron emission tomography/computed tomography imaging in well-differentiated thyroid cancers with negative iodine-131 scan high thyroglobulin and normal anti-thyroglobulin levels.
Döner RK; Sager S; Görtan FA; Topuz ÖV; Akyel R; Vatankulu B; Baran A; Teksoz S; Sönmezoglu K
J Cancer Res Ther; 2016; 12(2):1010-7. PubMed ID: 27461690
[TBL] [Abstract][Full Text] [Related]
8. Serum thyroglobulin improves the sensitivity of the McGill Thyroid Nodule Score for well-differentiated thyroid cancer.
Scheffler P; Forest VI; Leboeuf R; Florea AV; Tamilia M; Sands NB; Hier MP; Mlynarek AM; Payne RJ
Thyroid; 2014 May; 24(5):852-7. PubMed ID: 24341425
[TBL] [Abstract][Full Text] [Related]
9. The importance of inferior-superior thyroid veins sampling in the diagnosis of thyroid carcinomas.
Kutun S; Ay AA; Celik A; Turan U; Ulucanlar H; Cetin A
Endokrynol Pol; 2012; 63(3):202-5. PubMed ID: 22744626
[TBL] [Abstract][Full Text] [Related]
10. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
12. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
13. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer.
Aliyev A; Soundararajan S; Bucak E; Gupta M; Hatipoglu B; Nasr C; Siperstein A; Berber E
Surgery; 2015 Oct; 158(4):1089-93; discussion 1093-4. PubMed ID: 26212344
[TBL] [Abstract][Full Text] [Related]
14. Serum level of interleukin-17 and interleukin-35 as a biomarker for diagnosis of thyroid cancer.
Lu Y; Yuan Y
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C209-11. PubMed ID: 26506878
[TBL] [Abstract][Full Text] [Related]
15. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
16. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
[TBL] [Abstract][Full Text] [Related]
17. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
[TBL] [Abstract][Full Text] [Related]
18. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
19. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis.
Giovanella L; Treglia G; Sadeghi R; Trimboli P; Ceriani L; Verburg FA
J Clin Endocrinol Metab; 2014 Feb; 99(2):440-7. PubMed ID: 24285679
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
